Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Freedom Finance and Binance Join Forces in Digital Assets 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
REDWOOD CITY, Calif., May 03, 2018 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 9585106 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 9585106 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
